Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

783 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes.
Bakris GL, Ruilope LM, Anker SD, Filippatos G, Pitt B, Rossing P, Fried L, Roy-Chaudhury P, Sarafidis P, Ahlers C, Brinker M, Joseph A, Lawatscheck R, Agarwal R; FIDELIO-DKD and FIGARO-DKD Investigators. Bakris GL, et al. Among authors: rossing p. Kidney Int. 2023 Jan;103(1):196-206. doi: 10.1016/j.kint.2022.08.040. Epub 2022 Oct 28. Kidney Int. 2023. PMID: 36367466 Free article.
Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.
Sarafidis P, Agarwal R, Pitt B, Wanner C, Filippatos G, Boletis J, Tuttle KR, Ruilope LM, Rossing P, Toto R, Anker SD, Liu ZH, Joseph A, Ahlers C, Brinker M, Lawatscheck R, Bakris G; FIDELIO-DKD and FIGARO-DKD Investigators. Sarafidis P, et al. Among authors: rossing p. Clin J Am Soc Nephrol. 2023 May 1;18(5):602-612. doi: 10.2215/CJN.0000000000000149. Epub 2023 Apr 7. Clin J Am Soc Nephrol. 2023. PMID: 36927680 Free PMC article. Clinical Trial.
Estimated health economic impact of conducting urine albumin-to-creatinine ratio testing alongside estimated glomerular filtration rate testing in the early stages of chronic kidney disease in patients with type 2 diabetes.
Rossing P, Groehl F, Mernagh P, Folkerts K, Garreta-Rufas A, Harris J, Meredith K, Carter M, Åkerborg Ö, Wanner C, Hobbs FDR. Rossing P, et al. J Med Econ. 2023 Jan-Dec;26(1):935-943. doi: 10.1080/13696998.2023.2235922. J Med Econ. 2023. PMID: 37439218 Free article.
Discordance Between Creatinine-Based and Cystatin C-Based Estimated GFR: Interpretation According to Performance Compared to Measured GFR.
Wang Y, Adingwupu OM, Shlipak MG, Doria A, Estrella MM, Froissart M, Gudnason V, Grubb A, Kalil R, Mauer M, Rossing P, Seegmiller J, Coresh J, Levey AS, Inker LA. Wang Y, et al. Among authors: rossing p. Kidney Med. 2023 Aug 9;5(10):100710. doi: 10.1016/j.xkme.2023.100710. eCollection 2023 Oct. Kidney Med. 2023. PMID: 37753251 Free PMC article.
Estimating glomerular filtration rate in kidney transplant recipients: considerations for selecting equations.
Agarwal KA, Adingwupu OM, Tighiouart H, Miao S, Froissart M, Mauer M, Yang W, Torres V, de Borst M, Klintmalm G, Poggio ED, Rossing P, Velez R, Grubb A, Rule AD, Shaffi K, Chami A, Levey AS, Inker LA. Agarwal KA, et al. Among authors: rossing p. Kidney Int. 2024 Nov;106(5):991-995. doi: 10.1016/j.kint.2024.07.035. Epub 2024 Sep 12. Kidney Int. 2024. PMID: 39260523 No abstract available.
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes.
Schnell O, Battelino T, Bergenstal R, Birkenfeld AL, Ceriello A, Cheng A, Davies M, Edelman S, Forst T, Giorgino F, Green J, Groop PH, Hadjadj S, J L Heerspink H, Hompesch M, Izthak B, Ji L, Kanumilli N, Mankovsky B, Mathieu C, Miszon M, Mustafa R, Nauck M, Pecoits-Filho R, Pettus J, Ranta K, Rodbard HW, Rossing P, Ryden L, Schumm-Draeger PM, Solomon SD, Škrha J, Topsever P, Vilsbøll T, Wilding J, Standl E. Schnell O, et al. Among authors: rossing p. Cardiovasc Diabetol. 2023 Mar 16;22(1):59. doi: 10.1186/s12933-023-01788-6. Cardiovasc Diabetol. 2023. PMID: 36927451 Free PMC article.
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.
Tuttle KR, Hauske SJ, Canziani ME, Caramori ML, Cherney D, Cronin L, Heerspink HJL, Hugo C, Nangaku M, Rotter RC, Silva A, Shah SV, Sun Z, Urbach D, de Zeeuw D, Rossing P; ASi in CKD group. Tuttle KR, et al. Among authors: rossing p. Lancet. 2024 Jan 27;403(10424):379-390. doi: 10.1016/S0140-6736(23)02408-X. Epub 2023 Dec 15. Lancet. 2024. PMID: 38109916 Clinical Trial.
783 results